Education
About Us
Working with TipRanks
Follow Us
Chiome Bioscience Inc. (JP:4583)
:4583
Total Valuation
Chiome Bioscience Inc. has a market cap or net worth of ¥7.99B. The enterprise value is ¥6.88B.
Market Cap¥7.99B
Enterprise Value¥6.88B
Share Statistics
Chiome Bioscience Inc. has 69,453,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding69,453,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chiome Bioscience Inc.’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -68.07%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-68.07%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee12.62M
Profits Per Employee-20.91M
Employee Count47
Asset Turnover0.34
Inventory Turnover4.81
Valuation Ratios
The current PE Ratio of Chiome Bioscience Inc. is ―. Chiome Bioscience Inc.’s PEG ratio is 0.42.
PE Ratio―
PS Ratio12.25
PB Ratio6.47
Price to Fair Value6.47
Price to FCF-7.44
Price to Operating Cash Flow0.00
PEG Ratio0.42
Income Statement
In the last 12 months, Chiome Bioscience Inc. had revenue of 593.29M and earned -982.78M in profits. Earnings per share was -14.47.
Revenue593.29M
Gross Profit355.58M
Operating Income-979.77M
Pretax Income-979.54M
Net Income-982.78M
EBITDA-976.03M
Earnings Per Share (EPS)-14.47
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Chiome Bioscience Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change-31.95%
50-Day Moving Average112.40
200-Day Moving Average131.22
Relative Strength Index (RSI)50.77
Average Volume (3m)521.30K
Important Dates
Chiome Bioscience Inc. upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateNov 11, 2025
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Chiome Bioscience Inc. as a current ratio of 4.13, with Debt / Equity ratio of 23.32%
Current Ratio4.13
Quick Ratio3.99
Debt to Market Cap0.04
Net Debt to EBITDA0.97
Interest Coverage Ratio-310.55
Taxes
In the past 12 months, Chiome Bioscience Inc. has paid 3.24M in taxes.
Income Tax3.24M
Effective Tax Rate>-0.01
Enterprise Valuation
Chiome Bioscience Inc. EV to EBITDA ratio is -6.48, with an EV/FCF ratio of -6.48.
EV to Sales10.66
EV to EBITDA-6.48
EV to Free Cash Flow-6.48
EV to Operating Cash Flow-6.75
Balance Sheet
Chiome Bioscience Inc. has ¥1.47B in cash and marketable securities with ¥260.50M in debt, giving a net cash position of ¥1.21B billion.
Cash & Marketable Securities¥1.47B
Total Debt¥260.50M
Net Cash¥1.21B
Net Cash Per Share¥17.49
Tangible Book Value Per Share¥16.53
Margins
Gross margin is 59.93%, with operating margin of -165.14%, and net profit margin of -165.65%.
Gross Margin59.93%
Operating Margin-165.14%
Pretax Margin-165.10%
Net Profit Margin-165.65%
EBITDA Margin-164.51%
EBIT Margin-165.14%
Analyst Forecast
The average price target for Chiome Bioscience Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast25.28%
EPS Growth Forecast39.15%